NASDAQ:IRMD IRadimed (IRMD) Stock Forecast, Price & News $43.28 -0.18 (-0.41%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$42.92▼$43.7850-Day Range$43.28▼$50.3152-Week Range$26.00▼$51.04Volume17,211 shsAverage Volume37,462 shsMarket Capitalization$545.33 millionP/E Ratio37.31Dividend YieldN/APrice Target$54.00 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IRadimed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.8% Upside$54.00 Price TargetShort InterestHealthy1.02% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.51Based on 6 Articles This WeekInsider TradingSelling Shares$3.59 M Sold Last QuarterProj. Earnings Growth18.11%From $1.27 to $1.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.90 out of 5 starsMedical Sector44th out of 961 stocksSurgical & Medical Instruments Industry5th out of 97 stocks 2.5 Analyst's Opinion Consensus RatingIRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.00, IRadimed has a forecasted upside of 24.8% from its current price of $43.28.Amount of Analyst CoverageIRadimed has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.02% of the float of IRadimed has been sold short.Short Interest Ratio / Days to CoverIRadimed has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRadimed has recently decreased by 7.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIRadimed does not currently pay a dividend.Dividend GrowthIRadimed does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIRadimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for IRadimed is -0.85. Previous Next 2.5 News and Social Media Coverage News SentimentIRadimed has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IRadimed this week, compared to 1 article on an average week.MarketBeat Follows2 people have added IRadimed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,586,462.00 in company stock.Percentage Held by Insiders42.60% of the stock of IRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.61% of the stock of IRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IRadimed are expected to grow by 18.11% in the coming year, from $1.27 to $1.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRadimed is 37.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.24.Price to Earnings Ratio vs. SectorThe P/E ratio of IRadimed is 37.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.37.Price to Book Value per Share RatioIRadimed has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRadimed (NASDAQ:IRMD) StockIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More IRMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRMD Stock News HeadlinesSeptember 23, 2023 | money.usnews.comIradimed CorpSeptember 22, 2023 | msn.com4 Top Profitable Stocks to Invest in Using Net Income RatioSeptember 26, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 20, 2023 | americanbankingnews.comShort Interest in IRadimed Co. (NASDAQ:IRMD) Declines By 7.2%September 13, 2023 | finance.yahoo.comInsider Sell: Roger Susi Sells 10,000 Shares of iRadimed Corp (IRMD)September 6, 2023 | finance.yahoo.comIRADIMED CORPORATION to Participate at Upcoming Investor ConferencesSeptember 4, 2023 | finance.yahoo.comWith a 41% stake, IRadimed Corporation (NASDAQ:IRMD) insiders have a lot riding on the companyAugust 31, 2023 | msn.comIradimed (IRMD) Price Target Increased by 6.21% to 58.14September 26, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 25, 2023 | msn.comIRadimed Continues Ploughing Along With Superb Economic CharacteristicsAugust 24, 2023 | finance.yahoo.comZacks.com featured highlights Perdoceo Education, Boot Barn and iRadimedAugust 14, 2023 | finance.yahoo.comAre IRadimed Corporation (NASDAQ:IRMD) Investors Paying Above The Intrinsic Value?August 3, 2023 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Iradimed (IRMD)August 3, 2023 | finance.yahoo.comIRadimed (IRMD) Q2 Earnings and Revenues Beat EstimatesAugust 3, 2023 | msn.comiRadimed Non-GAAP EPS of $0.36 beats by $0.06, revenue of $16.13M beats by $0.47MAugust 3, 2023 | finance.yahoo.comIRADIMED CORPORATION Announces Second Quarter 2023 Financial ResultsJuly 27, 2023 | finance.yahoo.comIRADIMED CORPORATION to Hold 2023 Second Quarter Financial Results Conference Call on August 3rdJune 29, 2023 | finance.yahoo.comIRadimed (NASDAQ:IRMD) Knows How To Allocate Capital EffectivelyJune 15, 2023 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And IRadimed (NASDAQ:IRMD) Passed With EaseJune 9, 2023 | msn.comIRadimed: Incremental Profit Gains, Reiterate BuyJune 7, 2023 | fool.comIRadimed (NASDAQ: IRMD)May 18, 2023 | finance.yahoo.comiRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's WhyMay 16, 2023 | finance.yahoo.comIRadimed Corporation's (NASDAQ:IRMD) Stock Is Going Strong: Is the Market Following Fundamentals?May 10, 2023 | finance.yahoo.comIRADIMED CORPORATION Named a 2023 Best Small Company in America by ForbesMay 4, 2023 | finance.yahoo.comIRADIMED CORPORATION Announces First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comIRadimed (IRMD) Surpasses Q1 Earnings and Revenue EstimatesMay 3, 2023 | benzinga.comiRadimed Stock (NASDAQ:IRMD), DividendsSee More Headlines Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter. Email Address IRMD Company Calendar Last Earnings8/03/2023Today9/25/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees123Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.00 High Stock Price Forecast$60.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+24.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.16 Trailing P/E Ratio37.31 Forward P/E Ratio34.08 P/E GrowthN/ANet Income$12.83 million Net Margins24.53% Pretax Margin31.05% Return on Equity21.22% Return on Assets18.24% Debt Debt-to-Equity RatioN/A Current Ratio8.71 Quick Ratio7.60 Sales & Book Value Annual Sales$53.30 million Price / Sales10.23 Cash Flow$1.07 per share Price / Cash Flow40.46 Book Value$5.86 per share Price / Book7.39Miscellaneous Outstanding Shares12,600,000Free Float7,234,000Market Cap$545.33 million OptionableNot Optionable Beta0.99 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Roger E. Susi (Age 70)Founder, Chairman, CEO & Pres Comp: $586.04kMr. John F. Glenn (Age 61)CFO & Corp. Sec. Comp: $411.79kMr. Randy WaddellVP of Worldwide Sales & MarketingMr. Steve KachelmeyerVP of Regulatory Affairs & Quality AssuranceMr. Lynn NeuhardtVP of R&DMr. Chris WilliamsonExec. VP of Continuous Improvement & Information TechnologyMr. Matt GarnerControllerMore ExecutivesKey CompetitorsArtivionNYSE:AORTSilk Road MedicalNASDAQ:SILKSurmodicsNASDAQ:SRDXOrthofix MedicalNASDAQ:OFIXNevroNYSE:NVROView All CompetitorsInsiders & InstitutionsBarclays PLCSold 2,049 shares on 9/21/2023Ownership: 0.059%Roger E SusiSold 5,000 sharesTotal: $230,550.00 ($46.11/share)Roger E SusiSold 3,101 sharesTotal: $140,723.38 ($45.38/share)Roger E SusiSold 6,992 sharesTotal: $328,624.00 ($47.00/share)Alberta Investment Management CorpBought 5,490 shares on 8/24/2023Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions IRMD Stock - Frequently Asked Questions Should I buy or sell IRadimed stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks. What is IRadimed's stock price forecast for 2023? 1 brokers have issued 12 month target prices for IRadimed's shares. Their IRMD share price forecasts range from $48.00 to $60.00. On average, they anticipate the company's stock price to reach $54.00 in the next year. This suggests a possible upside of 24.8% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts. How have IRMD shares performed in 2023? IRadimed's stock was trading at $28.29 at the beginning of the year. Since then, IRMD shares have increased by 53.0% and is now trading at $43.28. View the best growth stocks for 2023 here. Are investors shorting IRadimed? IRadimed saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 76,000 shares, a decline of 7.2% from the August 15th total of 81,900 shares. Based on an average daily trading volume, of 36,800 shares, the short-interest ratio is currently 2.1 days. Currently, 1.0% of the shares of the stock are sold short. View IRadimed's Short Interest. When is IRadimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our IRMD earnings forecast. How were IRadimed's earnings last quarter? IRadimed Co. (NASDAQ:IRMD) issued its quarterly earnings results on Thursday, August, 3rd. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.05. The medical equipment provider had revenue of $16.13 million for the quarter, compared to analysts' expectations of $15.70 million. IRadimed had a net margin of 24.53% and a trailing twelve-month return on equity of 21.22%. How often does IRadimed pay dividends? What is the dividend yield for IRadimed? IRadimed announced a dividend on Monday, February 6th. Stockholders of record on Monday, February 13th will be given a dividend of $1.05 per share on Tuesday, February 21st. This represents a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, February 10th. This is a positive change from the stock's previous dividend of $1.00. Read our dividend analysis for IRMD. What ETF holds IRadimed's stock ? Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio. What guidance has IRadimed issued on next quarter's earnings? IRadimed issued an update on its third quarter 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.36-$0.38 for the period, compared to the consensus EPS estimate of $0.33. The company issued revenue guidance of $16.10 million-$16.30 million, compared to the consensus revenue estimate of $15.60 million. What other stocks do shareholders of IRadimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). What is IRadimed's stock symbol? IRadimed trades on the NASDAQ under the ticker symbol "IRMD." Who are IRadimed's major shareholders? IRadimed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.62%), BlackRock Inc. (3.94%), RK Capital Management LLC (2.29%), Bares Capital Management Inc. (2.20%), Ranger Investment Management L.P. (1.78%) and Russell Investments Group Ltd. (1.73%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi. View institutional ownership trends. How do I buy shares of IRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IRadimed's stock price today? One share of IRMD stock can currently be purchased for approximately $43.28. How much money does IRadimed make? IRadimed (NASDAQ:IRMD) has a market capitalization of $545.33 million and generates $53.30 million in revenue each year. The medical equipment provider earns $12.83 million in net income (profit) each year or $1.16 on an earnings per share basis. How many employees does IRadimed have? The company employs 123 workers across the globe. How can I contact IRadimed? IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The official website for the company is www.iradimed.com. The medical equipment provider can be reached via phone at (407) 677-8022, via email at investorrelations@iradimed.com, or via fax at 407-677-5037. This page (NASDAQ:IRMD) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRadimed Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.